Section Arrow
RYTM.NASDAQ
- Rhythm Pharmaceuticals
Quotes are at least 15-min delayed:2025/01/11 17:53 EST
Last
 56.17
-1.7 (-2.94%)
Day High 
56.99 
Prev. Close
57.87 
1-M High
60.52 
Volume 
591.07K 
Bid
54.46
Ask
57.56
Day Low
55.69 
Open
56.21 
1-M Low
53.39 
Market Cap 
3.56B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 57.68 
20-SMA 56.8 
50-SMA 57.77 
52-W High 68.58 
52-W Low 35.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.32/-1.22
Enterprise Value
3.56B
Balance Sheet
Book Value Per Share
0.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
77.43M
Operating Revenue Per Share
0.71
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/11 17:53 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.